Fidaxomicin’s domestic marketing progress and interpretation of relevant approval information

Fidaxomicin is a new macrolide antibiotic mainly used to treat Clostridioides difficile infection (CDI). Its mechanism of action is to selectively inhibit the RNA polymerase of Clostridium difficile, thereby blocking bacterial protein synthesis and achieving a bactericidal effect. Compared with traditional antibiotics, fidaxomicin has significant advantages in reducing the destruction of intestinal flora and reducing the recurrence rate, so it is widely recommended for the treatment of CDI worldwide.

In the domestic market, fidaxomicin has not yet been officially launched. The main reasons include that the drug registration and approval process, clinical trial data submission and production process verification are still in progress. Drug marketing approval must undergo strict review by the National Medical Products Administration (NMPA), including drug safety, effectiveness and comparative studies with existing treatment options. In addition, drugs must meet production quality standards and clinical indication certification before being marketed in China. These factors together determine that there is still uncertainty about the time to market fidaxomicin.

From the perspective of price and overseas market reference, the original drug of fidaxomicin is sold at a higher price overseas. For example, the price of each box of 200mg*20 tablets of the original drug is about more than 9,000 yuan. The price of the Lao version of the generic version of fidaxomicin is relatively affordable, about 5,000 yuan. Its pharmaceutical ingredients are basically the same as the original drug, and its efficacy can replace the original drug. The price difference reflects factors such as production costs, drug approvals and import tariffs, while also providing a potentially economically viable way for domestic patients to purchase drugs.

Taken together, it will still take time for fidaxomicin to be launched in China, and its price and medical insurance coverage are not yet known. Clinically, if patients need to use fidaxomicin to treat CDI, they can refer to overseas prices and generic drugs, but they need to pay attention to the formality and safety of the source of the drug. In the future, with the advancement of the domestic approval process and possible medical insurance negotiations, fidaxomicin is expected to achieve wider accessibility in the domestic market and provide an efficient and safe treatment option for patients with Clostridium difficile infection.

Reference link:https://www.drugs.com